Suppr超能文献

经皮穿刺注药港系统的临床获益:一项前瞻性观察研究。

Clinical benefit of power-injectable port systems: a prospective observational study.

机构信息

Department of Radiology, Charité Medical School, Humboldt University and Free University, Charitéplatz 1, D-10117 Berlin, Germany.

出版信息

Eur J Radiol. 2012 Mar;81(3):528-33. doi: 10.1016/j.ejrad.2011.01.038. Epub 2011 Mar 9.

Abstract

OBJECTIVE

To prospectively evaluate the clinical benefit of a central venous port system, which is approved for contrast media injection during contrast enhanced computed tomography.

MATERIALS AND METHODS

At a university teaching hospital, 98 patients (59 female, 39 male; median age 61.7 years; range 23-83) had a power-injectable central venous port catheter system implanted. All implantations were performed under ultrasonographic and fluoroscopic guidance by interventional radiologists. Procedure related immediate (up to 24 h after implantation), early (<30 days after implantation) and late complications were documented. The frequency of port system use for contrast enhanced computed tomography scans was also considered. Any port capsule migration was assessed indirectly by determining the catheter tip position. The intended follow-up period was 180 days.

RESULTS

An overall complication rate of 0.69 for 1,000 catheter days in 78 evaluated ports was recorded (12 ports affected, 15.4%). During the observational period, 40 of 104 contrast enhanced computed tomography scans were performed utilizing the port for contrast media administration (38.5%). 30 catheter tip retractions of more than 3 cm were observed in 82 patients (36.6%). Overall, tip dislocations were statistically more frequent in the female subgroup.

CONCLUSION

The complication rate found in this study is comparable to those, which have been published for standard port systems. The utilization of the device for contrast media injection during contrast enhanced computed tomography scans should be increased. Finally, the port capsule has to be carefully positioned and fixed to prevent migration.

摘要

目的

前瞻性评估中央静脉置管系统的临床获益,该系统已获准在增强 CT 期间注射对比剂。

材料和方法

在一所大学教学医院,98 名患者(59 名女性,39 名男性;中位年龄 61.7 岁;范围 23-83 岁)植入了可强力注射的中央静脉置管系统。所有植入均由介入放射科医生在超声和透视引导下进行。记录了与操作相关的即刻(植入后 24 小时内)、早期(植入后 30 天内)和晚期并发症。还考虑了使用该端口系统进行增强 CT 扫描的频率。通过确定导管尖端位置间接评估端口胶囊迁移的频率。预期的随访期为 180 天。

结果

在 78 个评估端口中,每 1000 个导管日的总体并发症率为 0.69(12 个端口受影响,15.4%)。在观察期间,104 次增强 CT 扫描中有 40 次(38.5%)使用该端口进行了造影剂给药。在 82 名患者中观察到 30 次导管尖端回缩超过 3 厘米。总体而言,女性亚组的尖端脱位更为频繁。

结论

本研究发现的并发症发生率与已发表的标准端口系统相似。应增加该设备在增强 CT 扫描期间注射造影剂的使用。最后,必须小心定位和固定端口胶囊,以防止迁移。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验